Bio Medica Laboratories share price
NSE: BMLLPharmaceuticals & Biotechnology
Bio Medica Laboratories Limited · Face value ₹10 Face value. The nominal value of one share as the company issued it, the unit its share capital is counted in and a dividend can be stated as a percentage of; it has no link to the share price. Face value in the glossary · Listed May 2026 · Issue price ₹139
Last close ₹154.90up ₹8.50 (5.81%)
Share price at the NSE close on 27 Oct 2026. Previous close ₹146.40.
27 Oct: open ₹146.00, high ₹154.90, low ₹146.00
Range of traded prices from listing on 29 May 2026 to 27 Oct 2026
₹101.50Low, 3 Jun 2026₹181.00High, 4 Sep 2026
- Market capMarket capitalisation. Share price times the number of shares: what the whole company is worth at the day's price. Market capitalisation: how it is worked out
- ₹195 Cr
- P/EPrice to earnings, trailing. Market cap divided by the profit of the last twelve months (the latest four quarters, or two half years for a company that reports half-yearly) that belongs to the company's own shareholders, after the share of the other owners of its subsidiaries: what investors pay for each rupee of a year's profit. Price to earnings, trailing: how it is worked out
- 16.69
- P/BPrice to book. Market cap divided by the net worth that belongs to the company's own shareholders, its assets less everything it owes and less the other owners' share of its subsidiaries, on its latest balance sheet. Price to book: how it is worked out
- Shares changed
- Dividend yieldDividend yield. Dividends paid per share in the twelve months to the day, as a percentage of the day's share price.
- Nonesince listing in May 2026
- ROEReturn on equity. Profit over the last twelve months (the latest four quarters, or two half years for a company that reports half-yearly) that belongs to the company's own shareholders, as a percentage of their net worth, the money they have in the business. Net worth is the latest balance sheet's; the one a year before is not on record.
- 44.2%
- Debt to equityDebt to equity. Borrowings divided by the whole group's net worth, the other owners of its subsidiaries included: rupees borrowed for each rupee of equity in the business. Lease liabilities are not counted: the results filings do not state them. From the balance sheet at the end of Mar 2026. Taken from the consolidated balance sheet, the company and its subsidiaries together; the P/E is on the company's own results until four consolidated quarters are filed.
- 1.97
- Volume, NSEVolume. Shares traded on the last trading day; delivery is the part buyers kept rather than sold again the same day. Volume in the glossary
- 1,10,000100.0% delivered
Results
Consolidated; ₹ crore.Bio Medica Laboratories half-yearly results
Year to Mar 2026
- Revenue
- ₹43 Cr
- Net profit
- ₹12 Cr
- Net marginNet margin. Net profit as a percentage of revenue: how much of each rupee of sales is left after every cost, interest and tax. Net margin in the glossary
- 27.3%
| ₹ crore | Mar 2026 |
|---|---|
| Revenue | 43.1 |
| Net profit | 11.8 |
| Net margin | 27.3% |
Consolidated. Years to March. Net profit is the whole group's, the other owners of its subsidiaries included; P/E and ROE use the company's own share.
Half year to Mar 2026
- Revenue
- ₹43 Cr
- Net profit
- ₹12 Cr
- Net margin
- 27.3%
| ₹ crore | Mar 2026 |
|---|---|
| Revenue | 43.1 |
| Net profit | 11.8 |
| Net margin | 27.3% |
Consolidated. The half year to Mar 2026, the first on record. Net profit is the whole group's, the other owners of its subsidiaries included; P/E and ROE use the company's own share.
Business segments
In the year to Mar 2026 the company reports one business segment, Medical products Business, which carries all its revenue.
Bio Medica Laboratories competitors and peers
Pharmaceuticals, 215 listed companies, priced on 28 Oct 2026. The table lists the 8 companies closest to Bio Medica Laboratories in market cap. Bio Medica Laboratories' own figures are from its last trade, on 27 Oct 2026.Healthcare companies
Where the company sits among the companies nearest its size
| Company | ||||||||
|---|---|---|---|---|---|---|---|---|
 Accretion PharmaceuticalsACCPL | 206 | 21.27 | 3.76 | +56.2% | +42.3% | 27.6% | – | 0.00% |
 Nectar LifesciencesNECLIFE | 201 | – | 0.35 | −99.7% | – | −31.9% | −15.4% | 0.00% |
 Kerala AyurvedaKERALAYUR | 196 | – | – | +10.4% | – | −257.3% | −24.1% | 0.00% |
 Syschem (India)SYSCHEM | 196 | – | 1.41 | +40.3% | – | – | 10.4% | 0.00% |
 Achyut HealthcareACHYUT | 194 | – | 5.50 | – | – | – | 0.2% | 0.00% |
 Coral LaboratoriesCORALAB | 179 | 9.33 | 0.86 | −5.4% | +7.2% | 9.4% | 7.6% | 0.40% |
 Oxygenta PharmaceuticalOXYGENTAPH | 177 | – | – | +20.6% | – | – | −15.1% | 0.00% |
 Brooks LaboratoriesBROOKS | 176 | 13.36 | 1.44 | −7.7% | +550.4% | 12.0% | 3.2% | 0.00% |
Market cap in ₹ crore. Growth is the last twelve months against the twelve before. A figure is left empty where it would rest on a loss or the company has under a year of results on record. ROE is the shareholders' profit over their net worth. ROCE is profit before interest and tax over the whole group's net worth plus borrowings, as in the figures at the top of the page.
Latest announcements
Routine notices left out.Bio Medica Laboratories announcements
Oct 2026
Sep 2026
28 Sep · Meeting
28 Sep
Recent sessions
The 9 trading days to 26 Oct 2026, as traded on NSE; the latest is at the top of the page.
| Date | Open | High | Low | Close | Average price | Volume | Delivery |
|---|---|---|---|---|---|---|---|
| 26 Oct 2026 | 146.00 | 155.00 | 144.95 | 146.40 | 146.22 | 1,62,000 | 95.7% |
| 23 Oct 2026 | 155.00 | 156.00 | 148.00 | 149.75 | 150.32 | 50,000 | 100.0% |
| 22 Oct 2026 | 155.00 | 155.00 | 155.00 | 155.00 | 155.00 | 1,000 | 100.0% |
| 19 Oct 2026 | 158.25 | 158.25 | 155.00 | 155.50 | 156.16 | 29,000 | 82.8% |
| 16 Oct 2026 | 156.00 | 167.00 | 156.00 | 164.50 | 161.55 | 40,000 | 95.0% |
| 15 Oct 2026 | 160.00 | 167.80 | 160.00 | 167.80 | 160.85 | 13,000 | 100.0% |
| 14 Oct 2026 | 163.10 | 163.20 | 163.05 | 163.05 | 163.12 | 3,000 | 66.7% |
| 13 Oct 2026 | 146.35 | 174.00 | 140.50 | 163.70 | 155.77 | 60,000 | 46.7% |
| 12 Oct 2026 | 151.30 | 151.95 | 148.00 | 150.00 | 149.86 | 5,000 | 60.0% |
Prices in ₹ per share as traded, not adjusted.
Company details
- NSE symbol
- BMLL
- ISIN
- INE1BKA01015
- Industry
- Pharmaceuticals & Biotechnology